BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 24361275)

  • 1. APOBEC3 multimerization correlates with HIV-1 packaging and restriction activity in living cells.
    Li J; Chen Y; Li M; Carpenter MA; McDougle RM; Luengas EM; Macdonald PJ; Harris RS; Mueller JD
    J Mol Biol; 2014 Mar; 426(6):1296-307. PubMed ID: 24361275
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanism of Enhanced HIV Restriction by Virion Coencapsidated Cytidine Deaminases APOBEC3F and APOBEC3G.
    Ara A; Love RP; Follack TB; Ahmed KA; Adolph MB; Chelico L
    J Virol; 2017 Feb; 91(3):. PubMed ID: 27881650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human and rhesus APOBEC3D, APOBEC3F, APOBEC3G, and APOBEC3H demonstrate a conserved capacity to restrict Vif-deficient HIV-1.
    Hultquist JF; Lengyel JA; Refsland EW; LaRue RS; Lackey L; Brown WL; Harris RS
    J Virol; 2011 Nov; 85(21):11220-34. PubMed ID: 21835787
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stability of APOBEC3F in the Presence of the APOBEC3 Antagonist HIV-1 Vif Increases at the Expense of Co-Expressed APOBEC3H Haplotype I.
    Yousefi M; Annan Sudarsan AK; Gaba A; Chelico L
    Viruses; 2023 Feb; 15(2):. PubMed ID: 36851677
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polymorphisms of the cytidine deaminase APOBEC3F have different HIV-1 restriction efficiencies.
    Mohammadzadeh N; Follack TB; Love RP; Stewart K; Sanche S; Chelico L
    Virology; 2019 Jan; 527():21-31. PubMed ID: 30448640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endogenous origins of HIV-1 G-to-A hypermutation and restriction in the nonpermissive T cell line CEM2n.
    Refsland EW; Hultquist JF; Harris RS
    PLoS Pathog; 2012; 8(7):e1002800. PubMed ID: 22807680
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Simian Immunodeficiency Virus Vif and Human APOBEC3B Interactions Resemble Those between HIV-1 Vif and Human APOBEC3G.
    Wang J; Shaban NM; Land AM; Brown WL; Harris RS
    J Virol; 2018 Jun; 92(12):. PubMed ID: 29618650
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interactions of host APOBEC3 restriction factors with HIV-1 in vivo: implications for therapeutics.
    Albin JS; Harris RS
    Expert Rev Mol Med; 2010 Jan; 12():e4. PubMed ID: 20096141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Catalytic activity of APOBEC3F is required for efficient restriction of Vif-deficient human immunodeficiency virus.
    Albin JS; Brown WL; Harris RS
    Virology; 2014 Feb; 450-451():49-54. PubMed ID: 24503066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The activity spectrum of Vif from multiple HIV-1 subtypes against APOBEC3G, APOBEC3F, and APOBEC3H.
    Binka M; Ooms M; Steward M; Simon V
    J Virol; 2012 Jan; 86(1):49-59. PubMed ID: 22013041
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV restriction by APOBEC3 in humanized mice.
    Krisko JF; Martinez-Torres F; Foster JL; Garcia JV
    PLoS Pathog; 2013 Mar; 9(3):e1003242. PubMed ID: 23555255
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiple APOBEC3 restriction factors for HIV-1 and one Vif to rule them all.
    Desimmie BA; Delviks-Frankenberrry KA; Burdick RC; Qi D; Izumi T; Pathak VK
    J Mol Biol; 2014 Mar; 426(6):1220-45. PubMed ID: 24189052
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Possible footprints of APOBEC3F and/or other APOBEC3 deaminases, but not APOBEC3G, on HIV-1 from patients with acute/early and chronic infections.
    Armitage AE; Deforche K; Welch JJ; Van Laethem K; Camacho R; Rambaut A; Iversen AK
    J Virol; 2014 Nov; 88(21):12882-94. PubMed ID: 25165112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Determinants of efficient degradation of APOBEC3 restriction factors by HIV-1 Vif.
    Baig TT; Feng Y; Chelico L
    J Virol; 2014 Dec; 88(24):14380-95. PubMed ID: 25275135
    [TBL] [Abstract][Full Text] [Related]  

  • 15. APOBEC3G and APOBEC3F Act in Concert To Extinguish HIV-1 Replication.
    Krisko JF; Begum N; Baker CE; Foster JL; Garcia JV
    J Virol; 2016 May; 90(9):4681-4695. PubMed ID: 26912618
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential sensitivity of murine leukemia virus to APOBEC3-mediated inhibition is governed by virion exclusion.
    Doehle BP; Schäfer A; Wiegand HL; Bogerd HP; Cullen BR
    J Virol; 2005 Jul; 79(13):8201-7. PubMed ID: 15956565
    [TBL] [Abstract][Full Text] [Related]  

  • 17. APOBEC3G restricts HIV-1 to a greater extent than APOBEC3F and APOBEC3DE in human primary CD4+ T cells and macrophages.
    Chaipan C; Smith JL; Hu WS; Pathak VK
    J Virol; 2013 Jan; 87(1):444-53. PubMed ID: 23097438
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The human immunodeficiency virus type 1 Vif protein reduces intracellular expression and inhibits packaging of APOBEC3G (CEM15), a cellular inhibitor of virus infectivity.
    Kao S; Khan MA; Miyagi E; Plishka R; Buckler-White A; Strebel K
    J Virol; 2003 Nov; 77(21):11398-407. PubMed ID: 14557625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distinct viral determinants for the packaging of human cytidine deaminases APOBEC3G and APOBEC3C.
    Wang T; Zhang W; Tian C; Liu B; Yu Y; Ding L; Spearman P; Yu XF
    Virology; 2008 Jul; 377(1):71-9. PubMed ID: 18495196
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Promiscuous RNA binding ensures effective encapsidation of APOBEC3 proteins by HIV-1.
    Apolonia L; Schulz R; Curk T; Rocha P; Swanson CM; Schaller T; Ule J; Malim MH
    PLoS Pathog; 2015 Jan; 11(1):e1004609. PubMed ID: 25590131
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.